Targovax Company
Targovax develops active immunotherapy in the form of cancer vaccines for application in post-operation treatments.
Technology:
Peptides and Proteins, Viral Vectors
Industry:
Peptides and Proteins
Headquarters:
Oslo, Oslo, Norway
Founded Date:
2010-01-01
Employees Number:
11-50
Funding Status:
IPO
Investors Number:
5
Total Funding:
38000000
Estimated Revenue:
$1M to $10M
Last Funding Date:
2022-01-12
Last Funding Type:
Grant
Register and Claim Ownership